Breast Carcinomas with Equivocal HER2/Neu Amplification: Morphologic Features, CEP17 Polysomy and HER2 Genetic Heterogeneity

被引：0

作者：

Astvatsaturyan, K. ^{[1
]}

Bose, S. ^{[1
]}

机构：

[1] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA

来源：

LABORATORY INVESTIGATION | 2012年 / 92卷

关键词：

D O I：

暂无

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

引用

页码：24A / 25A

页数：2

共 50 条

[1] Breast Carcinomas with Equivocal HER2/Neu Amplication: Morphologic Features, CEP17 Polysomy and HER2 Genetic Heterogeneity
Astvatsaturyan, K.
Bose, S.
MODERN PATHOLOGY, 2012, 25 : 24A - 25A
[2] HER2/Neu Gene Amplification Heterogeneity: The Significance of Cells with a 3:1 HER2/CEP17 Ratio
Layfield, L. J.
Schmidt, R.
LABORATORY INVESTIGATION, 2012, 92 : 49A - 49A
[3] HER2/neu Gene Amplification Heterogeneity: The Significance of Cells With a 3:1 HER2/CEP17 Ratio
Layfield, Lester J.
Schmidt, Robert L.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2012, 20 (06) : 543 - 549
[4] HER2/Neu Gene Amplification Heterogeneity: The Significance of Cells with a 3:1 HER2/CEP17 Ratio
Layfield, L. J.
Schmidt, R.
MODERN PATHOLOGY, 2012, 25 : 49A - 49A
[5] HER2 positive (HER2/CEP17 ratio≥2.0) invasive mammary carcinomas with average <4.0 HER2 and <2.0 CEP17 signals/cell: Clinicopathologic features, correlation with HER2 immunohistochemistry and response to neoadjuvant chemotherapy
Livasy, Chad A.
Limentani, Kimberly
Calhoun, Benjamin C.
Limentani, Steven
CANCER RESEARCH, 2015, 75
[6] Prevalence of polysomy 17 by OncoScan in Fluorescence In Situ Hybridization (FISH) HER2 Gene amplification by HER2 gene copy number of > 6.0 with HER2/CEP17 ratio of < 2.0 in breast cancer
Apple, Sophia
Murata-Collins, Joyce
LABORATORY INVESTIGATION, 2018, 98 : 45 - 45
[7] Prevalence of polysomy 17 by OncoScan in Fluorescence In Situ Hybridization (FISH) HER2 Gene amplification by HER2 gene copy number of > 6.0 with HER2/CEP17 ratio of < 2.0 in breast cancer
Apple, Sophia
Murata-Collins, Joyce
MODERN PATHOLOGY, 2018, 31 : 45 - 45
[8] Comparison of breast tumors with HER2 amplification and polysomy 17
Field, L. A.
Deyarmin, B.
Ellsworth, R. E.
Shriver, C. D.
CANCER RESEARCH, 2012, 72
[9] Chromosome 17 polysomy is common in breast cancer metastases and does not correlate with HER2/neu amplification or HER2/neu 2+staining by immunohistochemistry
Varghese, L.
Vanderwerf, S.
Sweeney, C.
Blair, C.
Forster, C.
Gulbahce, E.
LABORATORY INVESTIGATION, 2007, 87 : 52A - 53A
[10] Chromosome 17 polysomy is common in breast cancer metastases and does not correlate with HER2/neu amplification or HER2/neu 2+staining by immunohistochemistry
Varghese, L.
Vanderwerf, S.
Sweeney, C.
Blair, C.
Forster, C.
Gulbahce, E.
MODERN PATHOLOGY, 2007, 20 : 52A - 53A

← 1 2 3 4 5 →